Results 61 to 70 of about 481,186 (302)
Postmenopausal Vaginal Microbiome and Microbiota
The ovulatory cycle has a significant influence on the microbial composition, according to the action of estrogen and progesterone on the stratified squamous epithelium, due to an increase in epithelial thickness, glycogen deposition, and influence on ...
Nayara Santos de Oliveira +6 more
doaj +1 more source
The use of human adipose-derived stem cells in the treatment of physiological and pathological vulvar dystrophies [PDF]
“Vulvar dystrophy” is characterized by chronic alterations of vulvar trophism, occurring in both physiological (menopause) and pathological (lichen sclerosus, vulvar graft-versus-host disease) conditions.
CARELLA, SARA +4 more
core +4 more sources
Comparison of the effects of vaginal royal jelly and vaginal estrogen on quality of life, sexual and urinary function in postmenopausal women [PDF]
Introduction: Several causes can disturb the quality of life in postmenopausal women. Stress, urinary incontinence is one of the factors that can influence the quality of life of women, since they evade social activities and limit their behavior ...
Miraj, S., Rafiean, M., Seyyedi, F.
core +1 more source
Dynamics of the Mammalian Placental Metabolome in Placentogenesis and Embryonic Development
This study identifies three metabolic stages (E8.5, E9.5–10.5, E11.5–14.5) and two transition periods (E8.5–9.5, E10.5–11.5) in mouse placental development. NAD(H) emerges as a key dynamic metabolite that enhances embryonic growth through accelerated segmentation and increased proliferation of mouse embryonic stem cell (mESC)‐induced presomitic ...
Gang Chen +11 more
wiley +1 more source
Prenatal dexamethasone exposure (PDE) programs persistent podocyte developmental injury and adult glomerulosclerosis. Mechanistically, glucocorticoid receptor (GR) binds the miR‐135a‐5p promoter and recruits the histone acetyltransferase p300, increasing promoter histone acetylation and sustaining miR‐135a‐5p expression. Elevated miR‐135a‐5p suppresses
Xiaoqi Zhao +8 more
wiley +1 more source
Ospemifene May Not Treat Vulvar Atrophy: A Report of Two Cases
Introduction: Ospemifene (Osphena, Shionogi Inc, Florham, NJ, USA) is an estrogen agonist and antagonist approved by the U.S. Federal Drug Administration for the treatment of “moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due ...
Andrew T. Goldstein, MD +1 more
doaj +1 more source
ABSTRACT Postpartum hemorrhage (PPH) remains the leading cause of preventable maternal mortality despite standard interventions. Recent fibrinogen trials failed to improve outcomes, prompting interest in coagulation factor XIII (FXIII). FXIII functions as “molecular cement,” cross‐linking fibrin and stabilizing clots.
Jeremy W. Jacobs +8 more
wiley +1 more source
Vulvovaginal atrophy during menopause [PDF]
Objective: To present a basic clinical research based on current evidence about advanced treatment methods for vulvovaginal atrophy during menopause.And on principles of management of patients with vulvovaginal atrophy.Vulvovaginal atrophy (VVA) is a ...
Orru, A.J.
core
Abstract Recently, the concept ‘queer joy’ has gained interest in LGBT+ scholarship in the West. I use this scholarship as an entry point to explore how school‐attending LGBT+ youth express joy and how joy serves as a form of resistance against gender and sexuality norms in educational settings.
Dennis Francis
wiley +1 more source
Current treatment options for genitourinary syndrome
At the onset of menopause, the urogenital symptoms begin to develop simultaneously with vasomotor symptoms: vaginal soreness, itching and dryness, dyspareunia, etc.
E. V. Tikhomirova +2 more
doaj +1 more source

